Filing Overview
Filing type: Form 8-K, dated August 9, 2023, reporting events beginning August 6, 2023. The filing registrant is Tivic Health Systems, Inc., not Valion Bio, Inc. The filing text does not explain this company-name discrepancy.
Business Context and Transaction
On August 6, 2023, Tivic Health entered into a securities purchase agreement for a public offering of up to 33,173,000 shares of common stock at $0.041 per share. The offering closed on August 9, 2023, pursuant to the company’s effective Form S-3 shelf registration statement.
- Gross proceeds were approximately $1.4 million.
- Estimated net proceeds were approximately $1.2 million, after placement-agent fees, expenses, and other offering costs.
- Proceeds are intended for working capital and general corporate purposes.
Financial Metrics and Capitalization Impact
- The offering price was $0.041 per share.
- Maxim Group LLC received an 8.0% cash fee, reported as $108,807, plus reimbursement of up to $90,000 of certain expenses.
- The company issued Maxim warrants to purchase up to 1,326,920 shares, equal to 4.0% of the shares placed.
- The warrants have a five-year term, become exercisable six months after closing, and have an exercise price of $0.0492 per share.
- The transaction may materially dilute existing shareholders; the filing text does not provide the company’s pre-offering share count or pro forma ownership percentages.
- The filing does not provide revenue, profit, cash-flow, margin, debt, cash-balance, or liquidity metrics.
Material Changes and Other Terms
- The transaction increases common shares outstanding and creates additional potential dilution from the placement-agent warrants.
- The company agreed generally not to issue or announce additional securities for 30 days after closing, subject to exceptions.
- Officers and directors entered into 30-day lock-up agreements covering securities they hold, subject to exceptions.
- The purchase agreement includes customary closing conditions, representations, warranties, termination rights, indemnification obligations, and ongoing covenants.
Outlook, Risks, and Unusual Items
Management stated that the net proceeds will support working capital and general corporate purposes. No revenue or earnings guidance was provided.
- The offering was conducted on a reasonable-best-efforts basis, so proceeds depended on the amount placed.
- Future exercise of the placement-agent warrants could provide additional proceeds but would further dilute shareholders; the filing does not state that such warrants have been exercised.
- The filing does not quantify the company’s remaining liquidity, expected cash runway, or specific use of proceeds.
- The placement-agent warrants and the underlying shares were issued pursuant to an exemption from registration under Section 4(a)(2) and/or Regulation D.
Important Facts to Verify
- Confirm that the intended issuer is Tivic Health Systems, Inc., because the request metadata identifies Valion Bio, Inc.
- Verify the final number of shares sold and the resulting post-offering shares outstanding.
- Review the company’s subsequent filings for use of proceeds, liquidity, cash runway, and any additional financing.
- Confirm the terms, exercise status, and potential dilution from the 1,326,920 placement-agent warrants.
- Review Exhibits 10.1, 10.2, and 4.1 for the complete purchase-agreement, placement-agreement, and warrant terms.